Butyrylcholinesterase K Variant and Alzheimer's Disease Risk: a Meta-analysis

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2015 May 17

PMID 25978873

Citations 10

Authors

Zongcheng Wang

Yuren Jiang

Xi Wang

Yangsen Du

Dandan Xiao

Youchao Deng

Jinlian Wang

Affiliations

Soon will be listed here.

Abstract

Background: Although many studies have estimated the association between the butyrylcholinesterase (BCHE) K variant and Alzheimer's disease (AD) risk, the results are still controversial. We thus conducted this meta-analysis.

Material/methods: We searched NCBI, Medline, Web of Science, and Embase databases to find all eligible studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association.

Results: We found a significant association between BCHE K variant and AD risk (OR=1.20; 95% CI 1.03-1.39; P=0.02). In the stratified analysis by ethnicity, we observed a significant association between BCHE K variant and AD risk in Asians (OR=1.32; 95% CI 1.02-1.72; P=0.04). However, no significant association between BCHE K variant and AD risk in Caucasians was found (OR=1.14; 95% CI 0.95-1.37; P=0.16). When stratified by the age of AD onset, we found that late-onset AD (LOAD) was significantly associated with BCHE K variant (OR=1.44; 95% CI 1.05-1.97; P=0.02). No significant association between BCHE K variant and early-onset AD (EOAD) risk was observed (OR=1.16; 95% CI 0.89-1.51; P=0.27). Compared with non-APOE ε4 and non-BCHE K carriers, no significant association between BCHE K variant and AD risk was found (OR=1.11; 95% CI 0.91-1.35; P=0.30). However, APOE ε4 carriers showed increased AD risk in both non-BCHE K carriers (OR=2.81; 95% CI 1.75-4.51; P=0.0001) and BCHE K carriers (OR=3.31; 95% CI 1.82-6.02; P=0.0001).

Conclusions: The results of this meta-analysis indicate that BCHE K variant might be associated with AD risk.

Citing Articles

Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer's Disease in a Prospective Cohort Study.

Chuang Y, Varma V, An Y, Tanaka T, Davatzikos C, Resnick S J Alzheimers Dis. 2020; 75(2):417-427.

PMID: 32250307 PMC: 10845166. DOI: 10.3233/JAD-191335.

Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could Genotyping Be Helpful in Alzheimer's Therapy?.

Jasiecki J, Wasag B Biomolecules. 2019; 9(10).

PMID: 31601022 PMC: 6843418. DOI: 10.3390/biom9100592.

Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.

Jasiecki J, Limon-Sztencel A, Zuk M, Chmara M, Cysewski D, Limon J Sci Rep. 2019; 9(1):5223.

PMID: 30914707 PMC: 6435664. DOI: 10.1038/s41598-019-41578-3.

Genetic polymorphism analysis of patients with primary hyperhidrosis.

Simes B, Moore J, Brown T, Rushforth T, Bookout A, Richardson C Clin Cosmet Investig Dermatol. 2018; 11:477-483.

PMID: 30349345 PMC: 6187922. DOI: 10.2147/CCID.S176842.

The diabetic brain and cognition.

Riederer P, Korczyn A, Ali S, Bajenaru O, Choi M, Chopp M J Neural Transm (Vienna). 2017; 124(11):1431-1454.

PMID: 28766040 DOI: 10.1007/s00702-017-1763-2.

References

Bizzarro A, Guglielmi V, Lomastro R, Valenza A, Lauria A, Marra C . BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia. J Neural Transm (Vienna). 2010; 117(3):377-83. DOI: 10.1007/s00702-009-0358-y. View

Podoly E, Shalev D, Shenhar-Tsarfaty S, Bennett E, Ben Assayag E, Wilgus H . The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem. 2009; 284(25):17170-17179. PMC: 2719355. DOI: 10.1074/jbc.M109.004952. View

Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C . Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging. 2010; 32(12):2320.e15-32. DOI: 10.1016/j.neurobiolaging.2010.04.028. View

Alkalay A, Rabinovici G, Zimmerman G, Agarwal N, Kaufer D, Miller B . Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. Curr Alzheimer Res. 2012; 10(1):48-56. PMC: 3768143. View

Zimny A, Bladowska J, Neska M, Petryszyn K, Guzinski M, Szewczyk P . Quantitative MR evaluation of atrophy, as well as perfusion and diffusion alterations within hippocampi in patients with Alzheimer's disease and mild cognitive impairment. Med Sci Monit. 2013; 19:86-94. PMC: 3628917. DOI: 10.12659/msm.883757. View

Simao-Silva D, Bertolucci P, de Labio R, Payao S, Furtado-Alle L, Lehtonen Rodrigues Souza R . Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population. Chem Biol Interact. 2012; 203(1):358-60. DOI: 10.1016/j.cbi.2012.09.008. View

Kim D, Yeo S, Park J, Choi J, Lee T, Park S . Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. Gene. 2014; 545(2):185-93. DOI: 10.1016/j.gene.2014.05.031. View

Shenhar-Tsarfaty S, Berliner S, Bornstein N, Soreq H . Cholinesterases as biomarkers for parasympathetic dysfunction and inflammation-related disease. J Mol Neurosci. 2013; 53(3):298-305. DOI: 10.1007/s12031-013-0176-4. View

Zhang T, Jia Y . Meta-analysis of Ubiquilin1 gene polymorphism and Alzheimer's disease risk. Med Sci Monit. 2014; 20:2250-5. PMC: 4238758. DOI: 10.12659/MSM.891030. View

10.

McIlroy S, Crawford V, Dynan K, McGleenon B, Vahidassr M, LAWSON J . Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. J Med Genet. 2000; 37(3):182-5. PMC: 1734550. DOI: 10.1136/jmg.37.3.182. View

11.

Lee D, Liu H, Liu T, Chi C, Hong C . No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese. Am J Med Genet. 2000; 96(2):167-9. View

12.

Mattila K, Rinne J, Roytta M, Laippala P, Pietila T, Kalimo H . Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology. J Med Genet. 2000; 37(10):766-70. PMC: 1757160. DOI: 10.1136/jmg.37.10.766. View

13.

Prince J, Feuk L, Sawyer S, Gottfries J, Ricksten A, Nagga K . Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. Eur J Hum Genet. 2001; 9(6):437-44. DOI: 10.1038/sj.ejhg.5200651. View

14.

Kim K, Jhoo J, Lee J, Lee K, Lee D, Youn J . Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans. J Neural Transm (Vienna). 2001; 108(10):1159-66. DOI: 10.1007/s007020170005. View

15.

Lopez O, Becker J, Wisniewski S, Saxton J, Kaufer D, DeKosky S . Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002; 72(3):310-4. PMC: 1737770. DOI: 10.1136/jnnp.72.3.310. View

16.

Carson K, Geula C, Mesulam M . Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue. Brain Res. 1991; 540(1-2):204-8. DOI: 10.1016/0006-8993(91)90508-s. View

17.

Bartels C, Jensen F, Lockridge O, van der Spek A, Rubinstein H, Lubrano T . DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet. 1992; 50(5):1086-103. PMC: 1682596. View

18.

Lehmann D, Johnston C, Smith A . Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet. 1997; 6(11):1933-6. DOI: 10.1093/hmg/6.11.1933. View

19.

Guillozet A, Smiley J, Mash D, Mesulam M . Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol. 1997; 42(6):909-18. DOI: 10.1002/ana.410420613. View

20.

Brindle N, Song Y, Rogaeva E, Premkumar S, Levesque G, Yu G . Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease. Hum Mol Genet. 1998; 7(5):933-5. DOI: 10.1093/hmg/7.5.933. View